Cardiovascular complications of patients with aldosteronism associated with autonomous cortisol secretion

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2512-2518

  Nakajima, Yasuyo ^a   Yamada, Masanobu ^a   Taguchi, Ryo ^a   Satoh, Tetsurou ^a   Hashimoto, Koshi ^a   Ozawa, Atsushi ^a   Shibusawa, Nobuyuki ^a   Okada, Shuichi ^a   Monden, Tsuyoshi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; RENIN;

ADULT; AGE; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEXAMETHASONE SUPPRESSION TEST; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERALDOSTERONISM; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDIES; FEMALE; HEART DISEASES; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 79961231098     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2743     Document Type: Article

References (34)

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248 (Pubitemid 40523144)
2. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T 1995 Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18:370-373
3. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G 1999 Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33:261-266 (Pubitemid 29072226)
4. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA 2008 Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168:80-85
5. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M 2009 Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94:1125-1130
6. Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, Nuzzo V, Lombardi G 2000 Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85:1440-1448 (Pubitemid 32289484)
7. Terzolo M, Reimondo G, Bovio S, Angeli A 2004 Subclinical Cushing's syndrome. Pituitary 7:217-223 (Pubitemid 43115856)
8. Tsagarakis S, Vassiliadi D, Thalassinos N 2006 Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 29:471-482 (Pubitemid 44043366)
9. Stewart PM 2010 Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab 95:2618-2620
10. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A 2010 Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95:2736-2745
11. Adachi J, Hirai Y, Terui K, Nakano T, Fukuda Y, Suda T, Sasano H2003 A report of 7 cases of adrenal tumors secreting both cortisol and aldosterone. Intern Med 42:714-718 (Pubitemid 37021206)
12. Baert D, Nobels F, Van Crombrugge P 1995 Combined Conn's and Cushing's syndrome: an unusual presentation of adrenal adenoma. Acta Clin Belg 50:310-313
13. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:3266-3281
14. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T 2004 Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27:193-202 (Pubitemid 38489081)
15. Odagiri E, Naruse M, Tanabe A, Ohmura M, Oki T, Katabami T, Saitoh J, Nishika T, Shibata H, Doi M, Hirata Y 2007 [Problems of cortisol assay: confusion in the diagnosis of preclinical Cushing's syndrome]. Rinsho Byori 55:549-554
16. 2002 NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 19:1-25
17. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent adrenal mass ("incidentaloma") . Ann Intern Med 138:424-429 (Pubitemid 36262654)
18. Chiodini I, Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Viti R, Coletti F, Guglielmi G, Battista C, Carnevale V, Iorio L, Beck-Peccoz P, Arosio M, Ambrosi B, Scillitani A 2009 Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 94:3207-3214
19. 2007 [Guidelines for diagnosis and treatment of aortic aneurysm and aortic dissection (JCS 2006)]. J Cardiol 50:547-577
20. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM 2008 The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540 (Pubitemid 351656485)
21. Kidambi S, Raff H, Findling JW 2007 Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol 157:725-731
22. Abe K 1994 [Recent progress on the diagnosis and therapy of secondary hypertension]. Nippon Naika Gakkai Zasshi 83:1606-1613
23. Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G 2002 Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87:4872-4878 (Pubitemid 35316318)
24. Funder JW 2004 Is aldosterone bad for the heart? Trends Endocrinol Metab 15:139-142 (Pubitemid 38510491)
25. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275 (Pubitemid 17095145)
26. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121-125 (Pubitemid 40602484)
27. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 α-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121-1125 (Pubitemid 36262878)
28. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S 2007 Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754-1761 (Pubitemid 46648612)
29. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M 2009 Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail 2:608-615
30. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M 2006 Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47:656-664 (Pubitemid 43740235)
31. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831-1838 (Pubitemid 37296092)
32. Dorrance AM, Rupp NC, Nogueira EF 2006 Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47:590-595 (Pubitemid 43843881)
33. Osmond JM, Dorrance AM 2009 11β-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia. Endocrinology 150:713-719
34. Mihailidou AS, Loan Le TY, Mardini M, Funder JW 2009 Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54:1306-1312